MIAMI, June 18, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions in Orlando, Florida, June 21-24, 2024. The poster will be presented by Eric Sandhurst, PhD, Senior Program Manager at SAB, and will be published online in the journal ADA. Diabetes®.
American Diabetes Association 84Number Scientific Sessions
IND-Approved Evaluation of Tolerability and Safety of SAB-142 – a First-in-Class Fully Human Antithymocyte Immunoglobulin to Slow the Progression of Type 1 Diabetes
Date & Time: Sunday, June 23, 2024, 12:30pm – 1:30pm.
Location: Poster Hall – Poster No. 885-P
**All posters will be publicly displayed at the ADA 84th Scientific Session, June 21-24, 2024**
About the American Diabetes Association Scientific Sessions
The ADA’s 84th Scientific Sessions, the world’s largest scientific meeting focused on diabetes research, prevention and treatment, will be held June 21-24 in Orlando, Florida. More than 11,000 leading physicians, scientists and medical professionals from around the world are expected to convene both in-person and virtually to present cutting-edge diabetes research, treatment recommendations and therapeutic advances. Attendees will have exclusive access to thousands of unique research presentations and will participate in inspiring and engaging interactions with leading diabetes experts. Join the Scientific Sessions conversation by using #ADAScientificSessions on social media.
About SAB-142
SAB-142 is a human substitute for rabbit antithymocyte globulin (ATG). The mechanism of action of SAB-142 is similar to that of rabbit ATG and has been clinically validated in multiple clinical trials for type 1 diabetes, demonstrating its ability to slow disease progression in patients with new-onset or recent-onset stage 3 type 1 diabetes.
Two clinical trials have demonstrated that a single, low-dose administration of rabbit ATG modulates the body’s immune response, slowing the destruction of beta cells and preserving these cells’ ability to produce insulin, which the body needs to regulate blood sugar levels and carry out all human activities.
Like rabbit ATG, SAB-142 directly targets multiple immune cells involved in the destruction of pancreatic beta cells. By blocking immune cells from attacking beta cells, this treatment may protect insulin-producing beta cells. However, most people treated with rabbit ATG develop serum sickness and anti-drug antibodies from exposure to rabbit-derived antibodies. SAB-142 is a human antibody and is intended to enable safe and consistent rechallenge of type 1 diabetes, a lifelong chronic disease, without the risk of eliciting significant adverse immune responses that can occur with administration of animal ATG.
After receiving FDA IND approval in May, the company is currently working to expand its clinical program for SAB-142.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company focused on developing human multi-targeted, high-potency immunoglobulins (IgG) for the treatment and prevention of immune and autoimmune diseases without the need for human donors or convalescent plasma. The company’s lead product, SAB-142, targets T1D with a disease-modifying therapy approach aimed at changing the treatment paradigm by delaying onset and preventing disease progression. SAB’s DiversitAb™ Drug Development and Production System uses advanced genetic engineering and antibody science to develop the Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, capable of generating a diverse repertoire of specifically targeted, high-potency human IgGs that can address a wide range of critical unmet needs for human diseases without the need for convalescent plasma or human donors. For more information about SAB, please visit www.sab.com/. Click here for details Follow SAB LinkedIn.
Forward-Looking Statements
Certain statements contained in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “would,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or similar expressions that predict or indicate future events or trends or are not statements of historical fact. These forward-looking statements include, but are not limited to, statements about future events, including the development and effectiveness of our T1D program and other discovery programs.
These statements are based on SAB’s current expectations and are not intended to be, and should not be, relied upon by any investor as a guarantee, forecast, definitive statement or commitment of fact or probability. These statements are only current expectations or projections and are subject to known and unknown risks, uncertainties and other factors that may be beyond our control. Actual events or circumstances are difficult or impossible to predict, and these risks and uncertainties could cause the results, performance or achievements of our company or our industry to differ materially from those projected in these forward-looking statements. A detailed description of risks and uncertainties can be found under the section entitled “Risk Factors” in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as amended or supplemented from time to time, and other filings with the Securities and Exchange Commission, available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they are made, whether as a result of new information, future events or circumstances or otherwise.
contact address
Media Contact:
inquiry
Investor Relations:
Kevin Gardner
Life Sciences Advisor
kgardner@lifesciadvisors.com
Chris Calabrese
Life Sciences Advisor
ccalabrese@lifesciadvisors.com
